unknown
Stage
1
Investors
About
CellCrine develops a patented chemically defined basal media supplement (BAP-CDS) that improves cell culture performance across multiple cell types and aims to replace fetal bovine serum in bioprocessing, cell therapy, and cultivated meat production.
Explore CellCrine's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.